What Meftal Spas Treats: Main Uses and Benefits

Meftal Spas is primarily used to provide symptomatic relief for acute discomfort associated with internal muscle spasms. It offers supportive therapeutic benefit by addressing groups of symptoms that can appear suddenly and create noticeable interference with daily stability. The use of the medicine is relevant for symptomatic management in conditions linked to pain and spasms, such as acute menstrual cramps, spasmodic dysmenorrhea, and visceral spasms (colic-like pain).

Managing Acute Pain and Spasms

This medication is commonly applied in the therapeutic domain of primary dysmenorrhea, where it focuses on easing challenging symptoms associated with severe monthly period cramps. It helps manage the intensity of these acute episodes contributing to improved day-to-day comfort during a period of heightened symptoms by providing supportive relief during these episodes. The medication is relevant in clinical settings marked by heightened patient distress, often applied when symptoms become temporarily overwhelming, offering short-term supportive relief that contributes to easing the overall symptom load.

---

Quick Fact: Relief for Acute Symptomatic Pain

Easing Functional Discomfort

Meftal Spas is applied in situations where additional symptomatic support is needed for discomfort and when symptoms cluster into patterns requiring supportive management. This application helps address temporary functional strain and offers symptomatic relief that helps patients cope more steadily with difficult episodes. It is commonly used across conditions presenting with acute episodes and where symptoms may intensify temporarily, supporting the patient during difficult episodes by easing distress.

Regulatory References

1. contributing to improved day-to-day comfort during a period of heightened symptoms

Who Can and Cannot Use Meftal Spas? (Official Regulatory Information)

Meftal Spas is a combination drug containing an NSAID (Mefenamic Acid) and an anticholinergic (Dicyclomine). Eligibility for use is determined by contraindications and special restrictions related to both components, based strictly on official regulatory documentation.

Absolute Contraindications (Must Not Use)

Individuals who must not use this medicine include those with:

• Known hypersensitivity to the ingredients, aspirin, or other NSAIDs.
• Active gastrointestinal ulceration, bleeding, or perforation.
• Obstructive diseases of the GI tract or urinary tract (obstructive uropathy).
• Glaucoma or Myasthenia Gravis.
• Severe renal or hepatic impairment.
• Infants under 6 months of age and nursing mothers.
• Pain following Coronary Artery Bypass Graft (CABG) surgery.

Condition and Age Restrictions

Population/Condition	Regulatory Status
Children/Adolescents (< 14)	Use is not established or not recommended by age.
Older Adults (> 65)	Use with caution due to increased risk of adverse reactions; requires close monitoring.
Pregnancy	Contraindicated in the third trimester.
Impaired Fertility	Not recommended for women attempting to conceive.

Use is generally limited to short-term therapy for eligible adult patients who do not present any documented contraindications.

Interactions with other medicines and products

Meftal Spas is a combination medicine, and its interaction profile is defined by the risks associated with its two active components, Mefenamic Acid (an NSAID) and Dicycloverine (an Anticholinergic).

Contraindicated and High-Risk Combinations

Official regulatory documents classify certain combinations as contraindicated or high-risk due to potential interaction severity:

• Other Systemic Non-Aspirin NSAIDs (including COX-2 inhibitors): Co-administration is generally discouraged due to an increased risk of serious gastrointestinal ulceration and bleeding.
• Pramlintide: Co-use with Dicycloverine is formally contraindicated because of synergistic inhibition of gastrointestinal motility.

Pharmacodynamic and Exposure-Modifying Interactions

Documented interactions primarily involve effects on coagulation, blood pressure, and drug exposure:

• Oral Anticoagulants: Mefenamic Acid increases the risk of bleeding by displacing these agents from protein binding, enhancing the anticoagulant response.
• Low-Dose Aspirin: Mefenamic Acid can interfere with the anti-platelet effect of low-dose aspirin, which may compromise its cardioprotective treatment.
• Anti-hypertensives: Co-administration with the NSAID component may reduce the therapeutic efficacy of these agents and increase the risk of renal deterioration.
• Lithium: Mefenamic Acid can increase plasma Lithium concentrations by reducing its renal clearance.
• Other Anticholinergic Drugs: Combining with Dicycloverine may lead to additive anticholinergic adverse effects.

Administration Constraints

Administration timing rules are officially specified for certain substances:

• Antacids: Simultaneous use of antacids may interfere with the absorption of the Dicycloverine component and is typically advised to be avoided.
• Secretin Testing: Anticholinergic drugs must be discontinued for a specific period (at least five half-lives) before administering secretin for stimulation testing to ensure accurate results.

Meftal Spas utilizes two distinct pharmacological mechanisms that modulate specific enzyme and receptor activity, employing a dual-action approach to target key signaling pathways.

Modulation of Inflammatory Mediator Synthesis

The mefenamic acid component acts within the domain of cyclooxygenase (COX) enzyme-mediated signaling. It functions as a reversible, non-selective inhibitor of the COX-1 and COX-2 isoenzymes. This action modifies early molecular steps that limit the conversion of arachidonic acid, thereby reducing the synthesis of prostaglandins, which are potent lipid mediators involved in localized signaling cascades. This molecular alteration changes subsequent physiological responses.

Anticholinergic Modulation of Smooth Muscle Activity

The dicyclomine component primarily engages mechanisms that influence smooth muscle processes, particularly in the gastrointestinal and genitourinary systems. It exerts an anticholinergic effect via competitive inhibition of muscarinic acetylcholine receptors. Additionally, it exhibits a direct non-specific effect on the smooth muscle fiber. The resulting mechanistic cascade yields altered smooth muscle tone and reduced motility within the targeted systems.

How to Use Meftal Spas

This section describes the administration guidelines for the combination medication Meftal Spas (Mefenamic Acid and Dicycloverine).

---

Administration and Dosage Principles

Meftal Spas is administered via the oral route as a fixed-dose tablet. The standard adult dosing regimen is typically one tablet taken three times daily for the management of acute spasmodic pain, although some official protocols align with an initial dose of 500 mg (Mefenamic Acid equivalent) followed by 250 mg every six hours. The medication is intended for short-term, intermittent use only. For acute conditions like colic pain, the treatment course is generally limited to a maximum of three to seven days.

---

Administration Conditions and Constraints

To ensure proper use, the tablet must be administered preferably with or after food to meet specific intake conditions. The dosage unit must be swallowed whole with water and must not be crushed, broken, or chewed. Treatment initiation for primary dysmenorrhea is scheduled to occur at the onset of bleeding and associated pain.

---

Population-Specific Use

Official prescribing information includes specific rules for certain patient groups. Appropriate dose reduction is advised for older adults (geriatric patients) due to increased susceptibility to effects from the medication's components. Furthermore, the combination product is generally not recommended for use in children under 14 years of age.

Recent Clinical Evidence

Meftal Spas is a combination medication containing Mefenamic Acid (a nonsteroidal anti-inflammatory drug or NSAID) and Dicyclomine (an antispasmodic agent). Clinical studies evaluating the combination are primarily focused on two areas: the relief of spasmodic abdominal pain and the management of primary dysmenorrhea (menstrual cramps).

---

Efficacy and Therapeutic Focus

Research has shown that the dual mechanism of action may be beneficial for symptoms where both pain and muscle spasm are present, such as intestinal colic and menstrual cramps. Studies involving the NSAID component, Mefenamic Acid, have investigated its role in reducing pain and inflammation by influencing chemical mediators called prostaglandins.

Separately, Dicyclomine's efficacy has been studied for its muscle-relaxing effects on the smooth muscles of the gastrointestinal tract and uterus, which may contribute to the relief of acute cramping pain.

---

Safety and Monitoring Considerations

Recent regulatory advisories have brought increased attention to the safety profile of Mefenamic Acid. The Indian Pharmacopoeia Commission (IPC) issued an alert concerning the potential for Mefenamic Acid to be associated with Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome, a rare but serious type of allergic reaction.

In addition, clinical data on the NSAID component indicates a risk of gastrointestinal adverse events, including ulceration and bleeding, as is common with this class of medication. Furthermore, concerns regarding potential effects on renal (kidney) function, especially with prolonged use, have been noted in expert reviews. Monitoring for signs of severe hypersensitivity and organ-related issues is a consistent recommendation in clinical practice.

Key Studies & References

1. Efficacy of mefenamic acid and diclofenac in the treatment of menorrhagia and dysmenorrhea in dysfunctional uterine bleeding: a randomized comparative study
2. Systematic review and meta-analysis of the use of antispasmodics for the treatment of irritable bowel syndrome
3. Mefenamic Acid - LiverTox: Clinical and Research Information on Drug-Induced Liver Injury (assessment of hepatotoxicity risk)

Common questions about Meftal Spas (FAQ)

Q: Does Meftal Spas have official uses for abdominal pain not related to menstruation?

The official product information indicates that the combination of mefenamic acid and dicyclomine is used for the treatment of abdominal pain and colicky pain. This includes spasmodic pain associated with the intestines and with conditions like ureteric colic (pain from kidney stones) and biliary colic.

Q: Is it necessary to always take Meftal Spas with food to prevent side effects?

Regulatory documents advise that the medicine is administered with or immediately after food or with a glass of water. Regulatory documents state this condition is typically intended to help reduce the risk of common gastrointestinal side effects, such as stomach upset, which are associated with the non-steroidal anti-inflammatory drug (NSAID) component.

Q: What information is available about using Meftal Spas for Irritable Bowel Syndrome (IBS) symptoms?

The dicyclomine component of this medicine is recognized for its function as a smooth muscle relaxant in the gastrointestinal tract. Official information describes that this effect is utilized to address abdominal pain and discomfort, particularly for symptoms associated with Irritable Bowel Syndrome (IBS).

Q: Can taking Meftal Spas cause or worsen heartburn or acid reflux?

Gastrointestinal side effects, including common symptoms like heartburn or general stomach upset, are reported with this medicine. These symptoms are related to the mefenamic acid component, which belongs to the Non-Steroidal Anti-Inflammatory Drug (NSAID) class.

Q: Is there any official information on taking Meftal Spas for pain related to kidney stones?

The medicine is indicated for relieving colicky pain, which is severe pain caused by spasms in hollow organs. This includes pain associated with the ureters (ureteric colic), which is the pain often felt when kidney stones are passing.

Q: How quickly can a person typically expect to feel the pain relief effect after taking Meftal Spas?

Information on the drug's absorption indicates that the mefenamic acid component is rapidly absorbed following administration. The medicine's active mefenamic acid component is typically measured to reach its highest concentration in the blood plasma within one to four hours after administration.

Q: How long do the pain-relieving effects of a single dose of Meftal Spas usually last?

The product information states the dosing interval is often scheduled for administration every six hours as needed. This interval describes the period over which the effects of the dose are generally accounted for in its use guidelines.

Q: Are there known risks associated with consuming alcohol while taking Meftal Spas?

Official warnings describe that consuming alcohol is advised to be avoided while using this medicine. Combining the two can significantly increase the risk of serious side effects, including an elevated risk of stomach bleeding and increased central nervous system effects like excessive drowsiness or dizziness.

Q: Is there a generic formulation of the active ingredients in Meftal Spas?

The active ingredients, mefenamic acid and dicyclomine, are common chemical entities used in multiple formulations worldwide. Accordingly, the combination of these two ingredients is available under a variety of generic brand names in international markets.

Q: Does Meftal Spas have an effect on the amount or duration of menstrual bleeding?

The mefenamic acid component is officially used to treat heavy menstrual bleeding, a condition known as menorrhagia. This is because the NSAID component is recognized to influence the chemical processes that manage bleeding during the menstrual cycle.

Q: Is Meftal Spas effective for treating fever or flu-like symptoms?

Official documentation indicates that the mefenamic acid component possesses antipyretic (fever-reducing) activity. This effect is in addition to its primary function as an analgesic (pain-reliever) and anti-inflammatory agent.

Q: Can Meftal Spas be used for relief from common tension headaches?

Regulatory information notes that mefenamic acid is indicated for the relief of general headache. It has also been examined for use in conditions like perimenstrual migraine prophylaxis (preventative treatment around the menstrual cycle).

Q: Is Meftal Spas considered a narcotic or a habit-forming substance?

The medicine is a combination of a Non-Steroidal Anti-Inflammatory Drug (NSAID) and an Anticholinergic. Neither of these components is typically classified as a narcotic or scheduled as a controlled substance with a high potential for abuse.

Q: Does Meftal Spas have a known potential to cause changes in heart rate?

The dicyclomine component has the potential to cause cardiovascular effects. These may include transient changes in heart rate, such as tachycardia (fast heart rate), along with palpitations.

Q: Does Meftal Spas have a known effect on blood sugar levels?

Official product information notes that mefenamic acid has been associated with adverse effects in the metabolism category. Specifically, it has been linked to potential issues with glucose intolerance in patients who have diabetes.

Q: Can Meftal Spas cause temporary water retention or swelling?

Regulatory documents indicate that the mefenamic acid component, like other NSAIDs, has been associated with side effects concerning fluid balance. This includes the potential for fluid retention and the presence of edema (swelling).

Q: Is there a mechanism by which Meftal Spas can affect mood or cause nervousness?

The medicine may cause central nervous system (CNS) effects due to the dicyclomine component. Adverse reactions may include feelings of nervousness, agitation, confusion, and in some cases, other changes in mental state.

Q: Does Meftal Spas help relieve gas or bloating associated with cramps?

The dicyclomine component is designed to relax smooth muscles, particularly in the gut and uterus. This action, which is intended to relieve painful spasms and cramps, also works to relieve related symptoms, including bloating.

Official Storage and Disposal Instructions

Meftal Spas Tablets must be stored and disposed of according to strict regulatory requirements to ensure product integrity and public safety.

Storage Conditions

The required storage temperature is below 30 C, in a dry place, and protected from light. This is considered controlled room temperature storage. The tablets must be kept in their original packaging and away from heat and moisture. Child safety is mandatory: the medicine must be kept out of sight and reach of children.

Disposal Requirements

Unused or expired Meftal Spas must be discarded properly; it must not be flushed in the toilet or thrown into the drain. Disposal is often managed through authorized take-back programs, and patients should ask a pharmacist for guidance on proper pharmaceutical waste disposal.